股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/ ...

Core Viewpoint - The company has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for RMB 12.396 million, enhancing its strategic control over the regional high-end medical testing services in Southwest China [1] Group 1: Transaction Details - Wuhan Kangshengda has successfully won the bid for a 40% stake in Huaxi Kangshengda through the North Exchange public listing process [1] - The transaction was formalized on November 25, 2025, with a total consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the Southwest region, covering Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient and consistent execution of the overall strategy in the Southwest region [1] - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergistic effects between ICL-driven IVD product development and IVD service upgrades [1] Group 3: Management and Collaboration - The company will take full control over the management appointments, performance assessments, and resource allocation of Huaxi Kangshengda, improving the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the Southwest region [1] - This integration will strengthen the regional operational capabilities of the company [1]

Core Viewpoint - The company successfully acquired a 40% stake in Huaxi Kangshengda, enhancing its strategic position in the southwestern region of China and aligning with its overall business strategy [1] Group 1: Acquisition Details - Wuhan Kangshengda has successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1] - Following the completion of this transaction, Huaxi Kangshengda will become a wholly-owned subsidiary of the company [1] Group 2: Strategic Benefits - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [1] - The acquisition will strengthen the company's management over Huaxi Kangshengda's operations and strategic direction, ensuring efficient and consistent execution of the overall strategy in the southwestern region [1] Group 3: Operational Enhancements - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergies between ICL-driven IVD product development and IVD service upgrades [1] - The company will take full control of Huaxi Kangshengda's management appointments, performance assessments, and resource allocation, enhancing the execution efficiency of cross-regional projects [1] - The company aims to deepen its clinical and research collaboration with Sichuan University Huaxi Hospital, integrating channels, technology, and medical resources in the southwestern region to strengthen regional integrated operational capabilities [1]

Core Viewpoint - The acquisition of a 40% stake in Huaxi Kangshengda by Wuhan Kangshengda is a strategic move to enhance the company's control over its operations and align with its overall business strategy in the southwestern region of China [1][2]. Group 1: Transaction Details - Wuhan Kangshengda successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1]. - Following the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the company [2]. Group 2: Strategic Importance - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [2]. - The full ownership will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient execution of the overall strategy in the southwestern region [2]. - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergy between ICL-driven IVD product development and IVD service upgrades [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 關連交易 收購華西康聖達40%股權 收購事項 董事會欣然宣佈，武漢康聖達（一家中國綜合實體）透過北交所公開掛牌程序成 功競得華西健康科技持有的華西康聖達（一家中國綜合實體）40%股權。於2025 年11月25日，武漢康聖達與華西健康科技訂立產權交易合同，據此，武漢康 聖達同意收購，而華西健康科技同意出售華西康聖達40%股權，對價為人民幣 12,396,000元。 上市規則之涵義 華西康聖達為一家中國綜合實體。截至本公告日期，轉讓方為華西康聖達的主 要股東，因此在附屬公司層面為本公司的關連人士。因此，收購事項構成本公 司的關連交易。根據上市規則第14A.101條，由於董事會已批准收購事項，而獨 立非執行董事已確認收購事項的條款屬公平合理，且收購事項按 ...

Core Points - Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 524,000 shares at an average price of HKD 1.2717 per share, totaling approximately HKD 666,400 [1] - Following this transaction, Mialkos Tomasz Jakub's total shareholding rose to 72.912 million shares, increasing his ownership percentage from 6.95% to 7.00% [1] Summary by Category Shareholding Activity - Mialkos Tomasz Jakub acquired 524,000 shares on November 19, 2025 [2] - The average purchase price was HKD 1.2717 per share [2] - The total investment for this acquisition was about HKD 666,400 [1] Ownership Changes - After the purchase, Mialkos Tomasz Jakub's total shares held reached 72.912 million [2] - His ownership percentage increased from 6.95% to 7.00% [1]

致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年11月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/ ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

Group 1 - The core point of the news is that Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 262,500 shares at an average price of HKD 1.5325 per share, resulting in a total investment of approximately HKD 402,300 [1][2] - Following this transaction, Mialkos Tomasz Jakub's total shareholding increased to 62,480,500 shares, raising his ownership percentage from 5.97% to 6.00% [1][2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註 ...